Redeye provides its first take on Cellavision’s Q2 report 2025, published this morning.
Dynavox delivered another impressive report, with sales 8% above our forecast and 3% ahead of consen...
Redeye comments on the takeover offer on Bredband2 from Telia Company.
Q2 in brief: better overall Our impression is that Svedbergs Group's Q2 report is better than Factse...
Redeye provides a short comment on the Q2 2025 report from Sdiptech, which came in below our estimat...
Offer at SEK 3.25/share In a move that was not too unexpected, Telia made a cash offer of SEK 3.
Redeye state Acconeer’s Q2 2025 report fell short of its expectations on both sales and EBITDA.
Redeye updates on Evolution post Q2-results which were largely in line with our forecasts.
Redeye comments on the negative topline data in the TRIFOUR study and provides a new base case.
Redeye provides an update following SSH's Q2 2025 were sales increased by 5.
Redeye notes that Sivers’ Q2 2025 report confirms the company’s solid underlying development, with 4...
Net sales and EBIT were slightly below consensus (LSEG Data & Analytics) in Q2.
Redeye retains its positive view of Vertiseit following the Q2 report.
Redeye remains confident on the case although Q2 numbers came in a little shy of our expectations.
Q2: better momentum for the largest brands In Q1, Boråstapeter returned to organic growth.
Q2 expectations Studsvik will report its Q2 on 22 July, and we forecast sales of SEK 246m, +5% y-o-y...
Exitmarknaderna har vaknat till liv igen och VEF har använt del av likviden från årets tre exits til...
Redeye was hoping for even stronger top-line and earnings considering the new IP deal with Bosch whi...
Redeye comments on Avensia’s Q2 report, with sales and EBIT somewhat lower than anticipated.
Vitrolife faces a tough 2025, and we expect this to continue during H2 2025, at best, at a fading ra...
